Opinion
Video
Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing.
Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL
Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis
Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL